Evaluation of the GTX™ 5126 DES Coronary Stent System in the Treatment of Patients With a Lesion in the Coronary Artery

Key Inclusion Criteria: * Patient has discrete de novo lesion of a coronary artery with symptomatic ischemic heart disease * Planned treatment of one lesion with a single stent * Denovo type A, B1 lesions with a Reference diameter between 3.0 and 3.5mm and a lesion length between 5 and 16mm Key Exclusion Criteria: * Diabetic (HbA1C \>6.0) * Platelet count \< 100000 cells/mm3 or \> 700000 cells/mm3; WBC \< 3000 cells/mm3; or a hemoglobin \< 10 g/dl * Renal dysfunction with creatinine \> 2.0 mg/dl * Patient has a known pre-dilatation ejection fraction (EF) less than forty five (\<45%) * Myocardial infarction (MI) less than 3 months prior to intervention * Patient has type B2, C lesion * Reference artery diameter \<3.0 or \>3.6 mm * Target lesion length \< 5mm and \>16 mm * Other stenosis \>50% in target vessel * Known hypersensitivity or contraindication to aspirin, clopidogrel, ticlopidine, or cobalt chromium, or a sensitivity to contrast agent that, in the opinion of the investigator, cannot be adequately premedicated.